- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07228182
Effect of High-Intensity Transcranial Alternating Current Stimulation on Gambling Disorder: A Randomized Controlled Trial (HITACSRCT-GD)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Jiang Du, MD, PhD.
- Phone Number: +8602164906315
- Email: dujiangdou@163.com
Study Locations
-
-
-
Shanghai, China
- Shanghai Mental Health Center
-
Contact:
- Jiang Du, MD, PhD.
- Phone Number: +86 021 6490 6315
- Email: dujiangdou@163.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Aged 18-60, male or female, with 9 or more years of education, and able to complete questionnaire evaluation and behavioral tests;
- Meet DSM-5 (Diagnostic and Statistical Manual of mental disorders,DSM) diagnostic criteria for gambling disorder;
- Have gambled for at least one year (at least once a week);
- Normal vision and hearing, or within the normal range after correction;
- Agree to cooperate in the follow-up evaluation;
- No metal implantation in the head, no history of nerve problems or head injury, and no skin sensitivity.
Exclusion Criteria:
- Have severe cognitive impairment, such as a history of head trauma, -cerebrovascular disease, epilepsy, etc.;
- Have used drugs promoting cognitive function in the last 6 months;
- Have impaired intelligence (Intelligence Quotient<70);
- Abuse or dependence of psychoactive substances (except nicotine) in the last 5 years.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Intervention group for gambling addiction
A 40-minute transcranial alternating current stimulus intervention of real stimulus is conducted twice a day (at least 3 hours apart) for a total of 10 days in the intervention group of gambling addiction.
|
Three conductive electrodes are placed overhead.
In the 10/20 international placement system, a 4.45 9.53 cm electrode is placed on the forehead corresponding to Fpz, Fp1 and Fp2.
Two 3.18 3.81 cm electrodes are placed on the mastoid region of each side.
The tACS stimulation waveform includes ramp-up and ramp-down periods of 180 and 12 s, respectively.
The frequency of stimulation is 77.5Hz, and the current is 15mA.
|
|
Sham Comparator: Sham stimulation
A 40-minute transcranial alternating current stimulus intervention of sham stimulus is conducted twice a day (at least 3 hours apart) for a total of 10 days in the intervention group of gambling addiction.
|
Three conductive electrodes are placed overhead.
In the 10/20 international placement system, a 4.45 9.53 cm electrode is placed on the forehead corresponding to Fpz, Fp1 and Fp2.
Two 3.18 3.81 cm electrodes are placed on the mastoid region of each side.
The appearance of the above-mentioned equipment is identical to that of the real stimulation group devices, but it only simulates the electrical sensation produced at the beginning and end of stimulation.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change of the gambling symptoms
Time Frame: Baseline, immediately after the intervention, two weeks after the intervention, one month after the intervention, two months after the intervention, three months after the intervention
|
Gambling symptom severity will be measured by the Pathological Gambling Yale-Brown Obsessive Compulsive Scale (PG-YBOCS).
The total score of PG-YBOCS ranges from 0 to 40, in which higher scores indicate more severe pathological gambling symptoms.
|
Baseline, immediately after the intervention, two weeks after the intervention, one month after the intervention, two months after the intervention, three months after the intervention
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change of the risky decision-making performance
Time Frame: Baseline, two weeks after the intervention.
|
Risky decision-making performance will be assessed using the Balloon Analogue Risk Task (BART). Higher average pumps in the BART indicate greater risk-taking propensity. Feedback-related negativity (FRN) will be recorded using electroencephalography (EEG), with larger amplitude typically reflecting enhanced sensitivity to negative feedback. Pig dice game will be administered during functional magnetic resonance imaging (fMRI) scanning to assess risk-taking decision-making. Higher frequency of continued dice rolls indicates greater risk propensity. Neural activity in the prefrontal cortex and striatum will be analyzed, with increased activation typically associated with risk evaluation and reward processing. |
Baseline, two weeks after the intervention.
|
|
Change of the inhibitory control performance
Time Frame: Baseline, two weeks after the intervention.
|
Stop-signal task (SST) will be employed to measure inhibitory control.
Longer stop-signal reaction times (SSRT) indicate poorer response inhibition.
The N2/P3 components will be recorded using electroencephalography (EEG), with enhanced N2 amplitude and reduced P3 amplitude typically reflecting greater cognitive conflict and inhibitory processing efficiency, respectively.
|
Baseline, two weeks after the intervention.
|
|
Change of the resting state neural activity.
Time Frame: Baseline, two weeks after the intervention.
|
Resting-state functional magnetic resonance imaging (rsfMRI) will be used to assess intrinsic brain connectivity.
Lower amplitude of low-frequency fluctuations (ALFF) and reduced functional connectivity (FC) within the default mode network (DMN) may reflect altered neural efficiency.
Resting-state electroencephalography (rsEEG) will be employed to measure spontaneous neural oscillations.
Enhanced theta/beta ratio and reduced alpha power may indicate compromised regulatory control and cortical arousal, respectively.
|
Baseline, two weeks after the intervention.
|
|
Change of depressive symptoms
Time Frame: Baseline, immediately after the intervention, two weeks after the intervention, one month after the intervention, two months after the intervention, three months after the intervention
|
Depressive symptoms will be measured by the 17-item Hamilton Depression Rating Scale (HAMD-17).
The total score of HAMD-17 ranges from 0 to 52, in which higher scores mean a higher severity of depressive symptoms.
|
Baseline, immediately after the intervention, two weeks after the intervention, one month after the intervention, two months after the intervention, three months after the intervention
|
|
Change of anxiety symptoms
Time Frame: Baseline, immediately after the intervention, two weeks after the intervention, one month after the intervention, two months after the intervention, three months after the intervention
|
Anxiety symptoms will be measured by the 14-item Hamilton Anxiety Rating Scale (HAMA-14).
The total score of HAMA-14 ranges from 0 to 56, in which higher scores mean a higher severity of anxiety symptoms.
|
Baseline, immediately after the intervention, two weeks after the intervention, one month after the intervention, two months after the intervention, three months after the intervention
|
|
Change of the sleep quality
Time Frame: Baseline, immediately after the intervention, two weeks after the intervention, one month after the intervention, two months after the intervention, three months after the intervention
|
Sleep quality will be measured by the Pittsburgh Sleep Quality Index (PSQI).
The total score of PSQI ranges from 0 to 21, in which higher scores mean poorer sleep quality.
|
Baseline, immediately after the intervention, two weeks after the intervention, one month after the intervention, two months after the intervention, three months after the intervention
|
|
Change of the gambling craving
Time Frame: Baseline, immediately after the intervention, two weeks after the intervention, one month after the intervention, two months after the intervention, three months after the intervention
|
Gambling craving will be measured by the gambling craving Visual Analog Scale (VAS).
The total score of VAS ranges from 0 to 10, in which higher scores mean a higher level of gambling craving.
|
Baseline, immediately after the intervention, two weeks after the intervention, one month after the intervention, two months after the intervention, three months after the intervention
|
|
Side effect of the modulation
Time Frame: Immediately after the intervention
|
Side effects will be measured by the Treatment Emergent Symptom Scale (TESS).
The total score of TESS varies depending on symptom severity, in which higher scores indicate more significant adverse reactions.
|
Immediately after the intervention
|
|
Change of the self-control ability
Time Frame: Baseline, immediately after the intervention, two weeks after the intervention, one month after the intervention, two months after the intervention, three months after the intervention
|
Self-control ability will be measured by the Self-Control Scale (SCS).
Higher scores of SCS indicate better self-regulation and impulse control.
|
Baseline, immediately after the intervention, two weeks after the intervention, one month after the intervention, two months after the intervention, three months after the intervention
|
|
Change of the gambling symptom severity
Time Frame: Baseline, immediately after the intervention, two weeks after the intervention, one month after the intervention, two months after the intervention, three months after the intervention
|
Gambling symptom severity will be measured by the Gambling Symptom Assessment Scale (G-SAS).
The total score of G-SAS ranges from 0 to 48, in which higher scores mean more severe gambling-related symptoms.
|
Baseline, immediately after the intervention, two weeks after the intervention, one month after the intervention, two months after the intervention, three months after the intervention
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- JDu-017
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gambling Disorder
-
University of Nevada, Las VegasNot yet recruitingGambling Disorder | Pathological Gambling | Problem Gambling | Behavioral AddictionUnited States
-
Université Catholique de LouvainCentre Hospitalier Universitaire Vaudois; Cliniques universitaires Saint-Luc-... and other collaboratorsUnknownCraving | Gambling | Gambling Disorder | Gambling, Pathological | Gambling ProblemSwitzerland
-
ITAB - Institute for Advanced Biomedical TechnologiesNot yet recruitingAccelerated rTMS in Gambling Disorder: a Multicentric, Randomized, Sham-controlled Trial (arTMSinGD)Gambling | Gambling Disorder | Gambling, Pathological | Gambling Problem
-
Karolinska InstitutetCompleted
-
East Tennessee State UniversityNot yet recruitingGambling Disorder | Gambling ProblemUnited States
-
Region SkaneLund UniversityRecruitingGambling Disorder | Problem GamblingSweden
-
Universitat Jaume INot yet recruitingGambling Disorder | Problem GamblingSpain
-
University of ChicagoCompleted
-
Nantes University HospitalNot yet recruitingPsilocybin AsSisted pSychotherapy for the treatmENt of Gambling disordER : a Pilot Study (PASSENGER)Gambling DisorderFrance
-
Stanford UniversityKindbridge Research InstituteNot yet recruitingGambling Disorder | Gambling Problem | Mental Health Issue
Clinical Trials on HI-tACS
-
Shanghai Mental Health CenterNot yet recruitingAlcohol Use Disorder (AUD)China
-
Xuanwu Hospital, BeijingRecruitingNeuroimmune Diseases With InsomniaChina
-
Xuanwu Hospital, BeijingNot yet recruiting
-
Shanghai Mental Health CenterRecruitingTranscranial Alternating Current Stimulation | Schizophrenia; Negative TypeChina
-
Tongji UniversityEnrolling by invitationNegative Symptoms in Schizophrenia | Cognition FunctionChina
-
University Health Network, TorontoRecruitingLong COVID | Post Acute Sequelae of COVID-19 | Post COVID-19 ConditionCanada
-
University of HawaiiPennington Biomedical Research Center; United States Department of Agriculture...RecruitingDiet, HealthyUnited States
-
Boston University Charles River CampusNot yet recruitingAging | Memory | Noninvasive Brain Stimulation
-
Brendon Gurd, PhDUnknownTime-course of Mitochondrial Biogenic Gene and Protein Expression in Exercised Human Skeletal MuscleMitochondrial BiogenesisCanada
-
Medipol UniversityEnrolling by invitationAttention Deficit Disorder With Hyperactivity (ADHD)Turkey (Türkiye)